Intellia Therapeutics Inc (FRA:38I)
€ 11.365 -0.31 (-2.66%) Market Cap: 1.17 Bil Enterprise Value: 635.81 Mil PE Ratio: 0 PB Ratio: 1.27 GF Score: 56/100

Intellia Therapeutics Inc at Barclays Gene Editing & Gene Therapy Summit (Virtual) Transcript

Nov 15, 2021 / 02:00PM GMT
Release Date Price: €113.65 (+2.16%)
Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst

Good morning, everyone. My name is Gena Wang. I'm biotech analyst at the Barclays. Welcome to our fifth Gene Editing Gene Therapy Summit. It is my great pleasure to introduce our next speaker, John Leonard, President and Chief Executive Officer from Intellia. John, maybe I will hand over to you to give a brief overview, and we will dive into the Q&A.

John M. Leonard
Intellia Therapeutics, Inc. - President, CEO & Director

Good morning, Gena. It's great to be here again. So that was fun to take your questions. By way of introduction, Intellia Therapeutics, I think the best way to think about us is what we call a full spectrum genome editing company. And by that, we mean a CRISPR/Cas9 and all of its various forms platform that is applied to both the in vivo and the ex vivo setting. And we try to do that in a modular way from both sides, emphasizing systemic delivery on the in vivo. And as you know from work we've done before, we're very, very enthusiastic about our liponanoparticle

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot